StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) stock

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)

Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –

TG Therapeutics operating margin

Operating margin is operating income as a percentage of revenue.

TG Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was 17.1%. For fiscal 2025 it was 20.0%, against 12.7% the year before. The highest annual figure on record is 20.0% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202520.0%+7.3
FY2024Dec 31, 202412.7%+3.9
FY2023Dec 31, 20238.8%+7847.8
FY2022Dec 31, 2022-7839.0%−2684.7
FY2021Dec 31, 2021-5154.3%+174841.8
FY2020Dec 31, 2020-179996.1%−68775.7
FY2019Dec 31, 2019-111220.4%+3516.4
FY2018Dec 31, 2018-114736.8%−36636.8
FY2017Dec 31, 2017-78100.0%−26146.7
FY2016Dec 31, 2016-51953.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 20269.0%−15.7
Q1 FY2026Mar 31, 202617.0%+9.8
Q4 FY2025Dec 31, 202526.2%−1.5
Q3 FY2025Sep 30, 202518.2%+3.3
Q2 FY2025Jun 30, 202524.7%+12.7
Q1 FY2025Mar 31, 20257.1%+21.7
Q4 FY2024Dec 31, 202427.7%+56.1
Q3 FY2024Sep 30, 202414.8%−54.4
Q2 FY2024Jun 30, 202412.0%+289.9
Q1 FY2024Mar 31, 2024-14.6%+459.5
Q4 FY2023Dec 31, 2023-28.4%+96895.4
Q3 FY2023Sep 30, 202369.2%+37263.9
Q2 FY2023Jun 30, 2023-277.9%+6277.8
Q1 FY2023Mar 31, 2023-474.1%+2843.0
Q4 FY2022Dec 31, 2022-96923.8%−92919.1
Q3 FY2022Sep 30, 2022-37194.7%−33001.2
Q2 FY2022Jun 30, 2022-6555.7%−1540.1
Q1 FY2022Mar 31, 2022-3317.1%+7931.6
Q4 FY2021Dec 31, 2021-4004.6%+224369.1
Q3 FY2021Sep 30, 2021-4193.5%+221390.7
Q2 FY2021Jun 30, 2021-5015.7%+128787.0
Q1 FY2021Mar 31, 2021-11248.7%+120975.0
Q4 FY2020Dec 31, 2020-228373.7%−128476.3
Q3 FY2020Sep 30, 2020-225584.2%−65423.7
Q2 FY2020Jun 30, 2020-133802.6%−40265.8
Q1 FY2020Mar 31, 2020-132223.7%−40936.8
Q4 FY2019Dec 31, 2019-99897.4%+42602.6
Q3 FY2019Sep 30, 2019-160160.5%−69823.7
Q2 FY2019Jun 30, 2019-93536.8%−210234.2
Q1 FY2019Mar 31, 2019-91286.8%+18126.3
Q4 FY2018Dec 31, 2018-142500.0%−60828.9
Q3 FY2018Sep 30, 2018-90336.8%−7218.4
Q2 FY2018Jun 30, 2018116697.4%+191500.0
Q1 FY2018Mar 31, 2018-109413.2%–
Q4 FY2017Dec 31, 2017-81671.1%–
Q3 FY2017Sep 30, 2017-83118.4%–
Q2 FY2017Jun 30, 2017-74802.6%–

More TG Therapeutics figures

See a number that looks wrong?